Haleon plc: Proposed
off-market purchase alongside Pfizer Inc.
offering
30
September 2024: Haleon plc (the "Company" or
"Haleon") (LSE/NYSE: HLN) notes the announcement today by Pfizer
Inc. ("Pfizer") of its proposed offering of ordinary shares of
£0.01 each in the Company to institutional investors by way of an
accelerated bookbuild offering process (the "Proposed
Offering").
Haleon has agreed with Pfizer to make an
off-market purchase of approximately £230 million worth of ordinary
shares from Pfizer, subject to completion of the Proposed Offering.
The purchase price per ordinary share to be paid by Haleon in the
off-market purchase will be equal to the offering price per
ordinary share in the Proposed Offering.
The off-market purchase includes approximately
£114.6 million worth of ordinary shares, which represents the
remainder of the £500 million allocated to share buybacks in 2024
announced on 29 February 2024. Haleon intends to cancel these
ordinary shares and end its on-market share buyback programme
launched on 1 August 2024.
Separate to the remaining capital allocated to
buybacks in 2024, the off-market purchase includes approximately
£115.4 million worth of ordinary shares that will be held as
treasury shares for the purposes of satisfying Haleon's obligations
under its existing employee share plans in 2025.
Further details will be provided following
announcement by Pfizer of the results of the Proposed
Offering.
Amanda Mellor
Company Secretary
Enquiries
|
Investors
|
Media
|
|
Sonya
Ghobrial
|
+44 7392 784784
|
Zoë Bird
|
+44 7736 746167
|
|
Rakesh
Patel
|
+44 7552 484646
|
Gemma Thomas
|
+44 7985 175048
|
|
Emma White
|
+44 7823 523562
|
|
|
|
Email:
investor-relations@haleon.com
|
Email:
corporate.media@haleon.com
|
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in
consumer health, with a purpose to deliver better everyday health
with humanity. Haleon's product portfolio spans five major
categories - Oral Health, Pain Relief, Respiratory Health,
Digestive Health and Other, and Vitamins, Minerals and Supplements
(VMS). Its long-standing brands - such as Advil, Sensodyne,
Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and
Centrum - are built on trusted science, innovation and deep human
understanding.
For more information please visit
www.haleon.com
Not for release, publication or distribution in
the United States, Canada, Japan, Australia or any other state or
jurisdiction in which such release, publication or distribution
would be unlawful.